Natural Investments LLC Buys Shares of 20,152 Pfizer Inc. (NYSE:PFE)

Natural Investments LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 20,152 shares of the biopharmaceutical company's stock, valued at approximately $534,000.

Other institutional investors also recently modified their holdings of the company. PSI Advisors LLC grew its position in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 385 shares during the last quarter. Waddell & Associates LLC grew its stake in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock valued at $723,000 after acquiring an additional 388 shares during the period. Patriot Financial Group Insurance Agency LLC increased its stake in Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. raised its holdings in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 391 shares during the last quarter. Finally, Lipe & Dalton raised its stake in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Pfizer Trading Down 2.4 %

NYSE PFE opened at $26.00 on Wednesday. The stock has a market cap of $147.33 billion, a PE ratio of 18.44, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company's 50-day moving average price is $26.29 and its 200-day moving average price is $27.19. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 earnings per share. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.62%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Guggenheim restated a "buy" rating and set a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Finally, Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.